Biomerica, Inc. (OTCMKTS:BMRA) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Saturday.

Shares of Biomerica (OTCMKTS:BMRA) traded up $0.23 during trading hours on Friday, hitting $3.34. 48,526 shares of the stock traded hands, compared to its average volume of 9,319. Biomerica has a one year low of $1.53 and a one year high of $3.46.

Biomerica (OTCMKTS:BMRA) last issued its quarterly earnings data on Monday, October 16th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. The business had revenue of $1.44 million during the quarter, compared to the consensus estimate of $1.52 million. Biomerica had a negative return on equity of 18.93% and a negative net margin of 14.33%.

TRADEMARK VIOLATION NOTICE: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/11/04/biomerica-inc-bmra-upgraded-by-valuengine-to-hold.html.

Biomerica Company Profile

Biomerica, Inc is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians’ offices and over-the-counter drugstores).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Biomerica Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica Inc. and related companies with MarketBeat.com's FREE daily email newsletter.